SCHEMBL3690048

SCHEMBL3690048

CC(=O)NC1CN(C(=O)c2nc3c(C(F)(F)F)cc(-c4ccoc4)cn3c2Cl)CC1c1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.34
SPTLC2 O15270 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
EPHX1 P07099 1/20 0.32
CYP2C9 P11712 1/20 0.32
EPHX2 P34913 1/20 0.32
KCNH2 Q12809 1/20 0.32
CACNA1C Q13936 1/20 0.32
TLR2 O60603 2/20 0.31
TLR1 Q15399 2/20 0.31
USP2 O75604 1/20 0.31
NTRK1 P04629 1/20 0.31
TYRO3 Q06418 1/20 0.31
MERTK Q12866 1/20 0.31
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
RIPK1 Q13546 1/20 0.30
CCR5 P51681 2/20 0.30
SCD5 Q86SK9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7501105 1.00 SLC6A9 (0.34) SLC6A9SPTLC2SMN1; SMN2NPSR1EPHX1
SCHEMBL3692133 0.91 PDE4B (0.34) SLC6A9SPTLC2TLR2TLR1NTRK1
SCHEMBL7495706 0.91 PDE4B (0.34) SLC6A9SPTLC2TLR2TLR1NTRK1
SCHEMBL7496196 0.90 SLC6A9 (0.35) SLC6A9SPTLC2USP2NTRK1TYRO3
SCHEMBL3684175 0.90 SLC6A9 (0.35) SLC6A9SPTLC2USP2NTRK1TYRO3
Methane SCHEMBL4452839 0.88 SLC6A9 (0.33) SLC6A9USP2TYRO3MERTK
SCHEMBL3650212 0.87 TACR1 (0.34) TLR2TLR1USP2CCR5SCD5
SCHEMBL7491631 0.87 TACR1 (0.34) TLR2TLR1USP2CCR5SCD5
SCHEMBL3690401 0.87 USP2 (0.33) USP2CCR5SCD5
SCHEMBL7500064 0.87 USP2 (0.33) USP2CCR5SCD5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 SLC6A9 4294/4885SPTLC2 4115/4885SMN1; SMN2 3448/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 SLC6A9 4294/4885SPTLC2 4115/4885SMN1; SMN2 3448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.